Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective
Identifieur interne : 000A57 ( Istex/Corpus ); précédent : 000A56; suivant : 000A58Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective
Auteurs : Michael Soyka ; Jonathan ChickSource :
- The American Journal on Addictions [ 1055-0496 ] ; 2003-05-06.
Abstract
In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.
Url:
DOI: 10.1111/j.1521-0391.2003.tb00497.x
Links to Exploration step
ISTEX:1D0092757D72D0F1517FE5BF5DB4DDAE91DE167CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title><author><name sortKey="Soyka, Michael" sort="Soyka, Michael" uniqKey="Soyka M" first="Michael" last="Soyka">Michael Soyka</name><affiliation><mods:affiliation>The Psychiatric Hospital, University of Munich, Munich, Germany</mods:affiliation></affiliation></author><author><name sortKey="Chick, Jonathan" sort="Chick, Jonathan" uniqKey="Chick J" first="Jonathan" last="Chick">Jonathan Chick</name><affiliation><mods:affiliation>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jchick@compuserve.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1111/j.1521-0391.2003.tb00497.x</idno><idno type="url">https://api.istex.fr/document/1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A57</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title><author><name sortKey="Soyka, Michael" sort="Soyka, Michael" uniqKey="Soyka M" first="Michael" last="Soyka">Michael Soyka</name><affiliation><mods:affiliation>The Psychiatric Hospital, University of Munich, Munich, Germany</mods:affiliation></affiliation></author><author><name sortKey="Chick, Jonathan" sort="Chick, Jonathan" uniqKey="Chick J" first="Jonathan" last="Chick">Jonathan Chick</name><affiliation><mods:affiliation>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jchick@compuserve.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal on Addictions</title><idno type="ISSN">1055-0496</idno><idno type="eISSN">1521-0391</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-05-06">2003-05-06</date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="69">s69</biblScope><biblScope unit="page" to="80">s80</biblScope></imprint><idno type="ISSN">1055-0496</idno></series><idno type="istex">1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C</idno><idno type="DOI">10.1111/j.1521-0391.2003.tb00497.x</idno><idno type="ArticleID">AJAD497</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1055-0496</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Michael Soyka M.D.</name><affiliations><json:string>The Psychiatric Hospital, University of Munich, Munich, Germany</json:string></affiliations></json:item><json:item><name>Jonathan Chick M.A., MBChB, M.Phil., FRCP (Edin) FRC Psych</name><affiliations><json:string>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</json:string><json:string>E-mail: jchick@compuserve.com</json:string></affiliations></json:item></author><articleId><json:string>AJAD497</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.</abstract><qualityIndicators><score>7.949</score><pdfVersion>1.5</pdfVersion><pdfPageSize>486 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1217</abstractCharCount><pdfWordCount>4789</pdfWordCount><pdfCharCount>33657</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>180</abstractWordCount></qualityIndicators><title>Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title><genre><json:string>article</json:string></genre><host><volume>12</volume><publisherId><json:string>AJAD</json:string></publisherId><pages><total>1</total><last>s80</last><first>s69</first></pages><issn><json:string>1055-0496</json:string></issn><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1521-0391</json:string></eissn><title>The American Journal on Addictions</title><doi><json:string>10.1111/(ISSN)1521-0391</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>substance abuse</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>public health & health services</json:string><json:string>substance abuse</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>toxicologie</json:string></inist></categories><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1111/j.1521-0391.2003.tb00497.x</json:string></doi><id>1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>2003 American Academy of Addiction Psychiatry</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title><author xml:id="author-1"><persName><forename type="first">Michael</forename><surname>Soyka</surname></persName><roleName type="degree">M.D.</roleName><affiliation>The Psychiatric Hospital, University of Munich, Munich, Germany</affiliation></author><author xml:id="author-2"><persName><forename type="first">Jonathan</forename><surname>Chick</surname></persName><roleName type="degree">M.A., MBChB, M.Phil., FRCP (Edin) FRC Psych</roleName><email>jchick@compuserve.com</email><affiliation>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</affiliation></author></analytic><monogr><title level="j">The American Journal on Addictions</title><idno type="pISSN">1055-0496</idno><idno type="eISSN">1521-0391</idno><idno type="DOI">10.1111/(ISSN)1521-0391</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-05-06"></date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="69">s69</biblScope><biblScope unit="page" to="80">s80</biblScope></imprint></monogr><idno type="istex">1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C</idno><idno type="DOI">10.1111/j.1521-0391.2003.tb00497.x</idno><idno type="ArticleID">AJAD497</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.</p></abstract></profileDesc><revisionDesc><change when="2003-05-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1521-0391</doi><issn type="print">1055-0496</issn><issn type="electronic">1521-0391</issn><idGroup><id type="product" value="AJAD"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="AMERICAN JOURNAL ON ADDICTIONS">The American Journal on Addictions</title></titleGroup></publicationMeta><publicationMeta level="part" position="05000"><doi origin="wiley">10.1111/ajad.2003.12.issue-s1</doi><numberingGroup><numbering type="journalVolume" number="12">12</numbering><numbering type="supplement">s1</numbering></numberingGroup><coverDate startDate="2003-05-06">May‐June 2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley">10.1111/j.1521-0391.2003.tb00497.x</doi><idGroup><id type="unit" value="AJAD497"></id></idGroup><countGroup><count type="pageTotal" number="1"></count></countGroup><titleGroup><title type="tocHeading1">ARTICLES</title></titleGroup><copyright>2003 American Academy of Addiction Psychiatry</copyright><eventGroup><event type="firstOnline" date="2010-02-18"></event><event type="publishedOnlineFinalForm" date="2010-02-18"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-06-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-01"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst">s69</numbering><numbering type="pageLast">s80</numbering></numberingGroup><correspondenceTo>Address correspondence to Dr. Chick, Department of Psychiatry, University of Edinburgh, Edinburgh EH10 5HF, United Kingdom. E‐mail: <email>jchick@compuserve.com</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:AJAD.AJAD497.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received August 15, 2002; accepted December 30, 2002.</unparsedEditorialHistory><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="73"></count><count type="linksCrossRef" number="75"></count></countGroup><titleGroup><title type="main">Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Michael</givenNames><familyName>Soyka</familyName><degrees>M.D.</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2" corresponding="yes"><personName><givenNames>Jonathan</givenNames><familyName>Chick</familyName><degrees>M.A., MBChB, M.Phil., FRCP (Edin) FRC Psych</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="DE"><unparsedAffiliation>The Psychiatric Hospital, University of Munich, Munich, Germany</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="GB"><unparsedAffiliation>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><p>In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective</title></titleInfo><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Soyka</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>The Psychiatric Hospital, University of Munich, Munich, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jonathan</namePart><namePart type="family">Chick</namePart><namePart type="termsOfAddress">M.A., MBChB, M.Phil., FRCP (Edin) FRC Psych</namePart><affiliation>Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom</affiliation><affiliation>E-mail: jchick@compuserve.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2003-05-06</dateIssued><edition>Received August 15, 2002; accepted December 30, 2002.</edition><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">73</extent></physicalDescription><abstract lang="en">In thirteen of sixteen placebo‐controlled trials in Europe, acamprosate increased abstinence in detoxified alcohol‐dependent patients. It is approved in most EU countries. Its action at N‐methyl‐D‐aspartate (NMDA) receptors appears to account for many of its effects. The number needed to treat in the fifteen trials suitable for meta‐analysis has been calculated at 8.15. Trials of naltrexone in Europe have shown less clear evidence of efficacy than trials of acamprosate, whether abstinence or relapse to heavy drinking is used as the outcome criterion. With reduction in heavy drinking days as the criterion, naltrexone compared favorably to acamprosate in an open study in moderate alcohol dependence; one double‐blind study has pointed to an advantage of the combination of naltrexone with acamprosate over either drug. To date, there are no trials published of nalmefene in European clinics. While many centers routinely offer a trial of acamprosate to newly detoxified patients aiming for abstinence, naltrexone usage varies. Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability.</abstract><relatedItem type="host"><titleInfo><title>The American Journal on Addictions</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">1055-0496</identifier><identifier type="eISSN">1521-0391</identifier><identifier type="DOI">10.1111/(ISSN)1521-0391</identifier><identifier type="PublisherID">AJAD</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s1</number></detail><extent unit="pages"><start>s69</start><end>s80</end><total>1</total></extent></part></relatedItem><identifier type="istex">1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C</identifier><identifier type="DOI">10.1111/j.1521-0391.2003.tb00497.x</identifier><identifier type="ArticleID">AJAD497</identifier><accessCondition type="use and reproduction" contentType="copyright">2003 American Academy of Addiction Psychiatry</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1D0092757D72D0F1517FE5BF5DB4DDAE91DE167C
|texte= Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective
}}
| This area was generated with Dilib version V0.6.29. |  |